Clinical Trials | June 04, 2024
Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Subscribe To Our Newsletter & Stay Updated
